Treatment Decision-Making for Leptomeningeal Metastasis After TKI Resistance in EGFR-Mutant Lung Cancer: A Comprehensive Review on Staging, Resistance Patterns, and Multimodal Interventions - Summary - MDSpire
Advertisement
Treatment Decision-Making for Leptomeningeal Metastasis After TKI Resistance in EGFR-Mutant Lung Cancer: A Comprehensive Review on Staging, Resistance Patterns, and Multimodal Interventions
To summarize management strategies for leptomeningeal metastasis in EGFR-mutant NSCLC patients specifically after TKI resistance.
Key Findings:
Leptomeningeal metastasis poses significant clinical challenges due to tumor heterogeneity and resistance mechanisms.
Current treatment strategies lack standardized protocols and require personalized approaches, emphasizing the need for a clinical decision-making pathway.
Combining therapies can improve neurological prognosis and survival rates, but comes with toxicity and logistical challenges.
Interpretation:
A multimodal approach is essential for optimizing treatment in patients with leptomeningeal metastasis after TKI resistance, with a focus on a clinical decision-making pathway and careful consideration of individual patient factors.
Limitations:
Lack of standardized treatment protocols.
Challenges in drug delivery across the blood-brain barrier.
Toxicity and unpredictability of treatment efficacy.
Conclusion:
Improving identification of resistance mechanisms, enhancing CNS drug delivery, and building stronger collaborative care models are crucial for better outcomes in this patient population.
